Antibacterial Agents | p. 1 |
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious Diseases | p. 3 |
Aminoglycosides | p. 21 |
Aztreonam | p. 45 |
Beta-lactam and Beta-lactamase Inhibitor Combinations (Amoxicillin/Clavulanic, Ampicillin/Sulbactam, Piperacillin/Tazobactam, Ticarcillin/Clavulanic) | p. 55 |
Carbapenems (Biapenem, Ertapenem, Faropenem, Imipenem, Meropenem, Panipenem) | p. 71 |
Cephalosporins | p. 89 |
Chloramphenicol | p. 121 |
Clindamycin | p. 131 |
Daptomycin | p. 149 |
Fosfomycin | p. 163 |
Fusidic Acid | p. 171 |
Glycopeptides (Dalbavancin, Oritavancin, Teicoplanin, Vancomycin) | p. 181 |
Ketolides (Telithromycin, Cethromycin) | p. 201 |
Linezolid and Other Oxazolidinones | p. 223 |
Macrolides | p. 243 |
Metronidazole | p. 281 |
Mupirocin | p. 293 |
Nitrofurantoin | p. 305 |
Penicillins | p. 309 |
Quinolones | p. 337 |
Quinupristin/Dalfopristin | p. 367 |
Rifamycins for Mycobacterial Infections | p. 383 |
Rifamycins for Nonmycobacterial Infections | p. 403 |
Sulfonamides | p. 455 |
Tetracyclines and Analogues | p. 461 |
Tigecycline | p. 477 |
Trimethoprim and Trimethoprim-Sulfamethoxazole (Cotrimoxazole) | p. 485 |
Antimycobacterial Agents | p. 501 |
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial Infections | p. 503 |
Cycloserine | p. 517 |
Ethambutol | p. 523 |
Ethionamide | p. 533 |
Isoniazid (INH) | p. 539 |
Para-Aminosalicyclic Acid | p. 551 |
Pyrazinamide | p. 559 |
Antifungal Agents | p. 571 |
Antifungal Agents: In vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination Therapy | p. 573 |
Amphotericin B | p. 591 |
Azoles (Clotrimazole, Fluconazole, Itraconazole, Ketoconazole, Miconazole, Voriconazole) | p. 609 |
Echinocandins (Caspofungin) | p. 637 |
Flucytosine | p. 651 |
Nystatin | p. 669 |
Antiviral Agents | p. 679 |
Abacavir | p. 681 |
Adefovir | p. 691 |
Amantadine, Rimantadine, and Related Agents | p. 705 |
Cidofovir | p. 731 |
Enfuvirtide and Other Fusion Inhibitors | p. 747 |
Ganciclovir | p. 757 |
Influenza Neuraminidase Inhibitors (Oseltamivir and Zanamivir) | p. 773 |
Interferons | p. 791 |
Lamivudine and Emtricitabine | p. 803 |
Nonnucleoside Analogues (Delavirdine, Efavirenz, Nevirapine) | p. 817 |
Nucleoside Analogues (Acyclovir, Famciclovir, Penciclovir, Valacyclovir) | p. 835 |
Nucleoside Analog Reverse Transcriptase Inhibitors (Didanosine, Zalcitabine, Zidovudine) | p. 845 |
Protease Inhibitors (Amprenavir, Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir) | p. 865 |
Ribavirin | p. 909 |
Stavudine | p. 923 |
Tenofovir | p. 935 |
Antiparasitic Agents | p. 947 |
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Parasitic Infections | p. 949 |
4-Aminoquinolines (Amodiaquine, Chloroquine) | p. 961 |
Antimonials (Meglumine antimoniate, Sodium stibogluconate) | p. 973 |
Artemisinin and Its Derivatives | p. 981 |
Atovaquone and Atovaquone-Proguanil | p. 1003 |
Benzimidazoles (Albendazole, Mebendazole, Thiabendazole, Triclabendazole) | p. 1021 |
Benznidazole | p. 1037 |
Bithionol | p. 1039 |
Diloxanide Furoate | p. 1041 |
Eflornithine | p. 1043 |
Emetine and Dehydroemetine | p. 1047 |
Folate Antagonists | p. 1049 |
Furazolidone | p. 1071 |
Halofantrine | p. 1075 |
Iodoquinol | p. 1079 |
Ivermectin | p. 1081 |
Levamisole | p. 1089 |
Mefloquine | p. 1091 |
Melarsoprol | p. 1105 |
Metrifonate | p. 1109 |
Niclosamide | p. 1113 |
Nifurtimox | p. 1115 |
Nitazoxanide | p. 1117 |
Oxamniquine | p. 1119 |
Pentamidine | p. 1123 |
Piperazine | p. 1127 |
Piperazine: Diethylcarbamazine | p. 1129 |
Praziquantel | p. 1135 |
Primaquine | p. 1145 |
Pyrantel Pamoate | p. 1161 |
Pyrvinium Pamoate | p. 1163 |
Quinacrine | p. 1165 |
Quinine and Quinidine | p. 1167 |
Suramin | p. 1195 |
Table of Contents provided by Rittenhouse. All Rights Reserved. |